Xcout IntelArvinas, Inc.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Subscribe to see Arvinas, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Arvinas, Inc. at a glance
Arvinas, Inc. is a biotech company headquartered in New Haven, United States, founded in 2013. It is publicly listed (ARVN) with a market capitalisation of $468.4M. Xcout tracks 20 named people at Arvinas, Inc., including Randy Teel (CEO, President & Director). Xcout recorded 6 job postings from Arvinas, Inc. in the last 90 days.
Arvinas, Inc. leadership
- Randy TeelCEO, President & Director
- Andrew SaikChief Financial Officer & Treasurer
- Angela CacaceChief Scientific Officer
- David LoomisVice President & Chief Accounting Officer
- Steve WeissSenior Vice President & Chief Human Resources Officer
- Dr. Craig CrewsFounder
14 more named people on record for Arvinas, Inc., with roles, board committees and tenure — see the full roster →
Arvinas, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $18.3M | 1 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Arvinas, Inc.
Xcout recorded 6 job postings from Arvinas, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Arvinas, Inc.'s hiring signals →
Investors
Get Arvinas, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Arvinas, Inc. in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access